The New York Times analyzes the process whereby Celebrex, an arthritis drug, was promoted by Prizer despite knowing that it was no more effective or safer than other drugs. “Pfizer and its partner. Pharmacia, presented the results from the first six months of a yearlong study rather than the whole thing.” Pfizer defends its decision by saying that 33 million Americans have taken the drug.
Enjoyed what you just read? Consider a donation to help us continue to produce content, provide up-to-date research news, offer continuing education courses, and continue building a community for exploring alternatives to the current paradigm of mental health. All donations are tax deductible.